In the present case report, we demonstrated that the mitogen-activated protein kinase (MEK) inhibitor trametinib combined with dasatinib display a safe and effective treatment profile in patients with Ph+ ALL. This evidence concerns the gene MAP2K7 and acute lymphoblastic leukemia.